Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNT033
MIFTS: 54

Central Nervous System Cancer

Categories: Cancer diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Central Nervous System Cancer

About this section

MalaCards integrated aliases for Central Nervous System Cancer:

Name: Central Nervous System Cancer 12 56 15 17
Malignant Neoplasm of Central Nervous System 12
Neoplasm of the Central Nervous System 6
Neoplasm of Central Nervous System 12
Central Nervous System Neoplasms 45
Central Nervous System Neoplasm 17
Central Nervous System Tumors 12
Central Nervous System Tumor 12
Malignant Tumor of Cns 12
Cns Neoplasm 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:3620
MeSH 45 D016543
NCIt 51 C4627 C9293
SNOMED-CT 69 93744007
ICD10 34 C72.9
Sources

Summaries for Central Nervous System Cancer

About this section
Disease Ontology : 12 A nervous system cancer that is located in the central nervous system.

MalaCards based summary : Central Nervous System Cancer, also known as malignant neoplasm of central nervous system, is related to central nervous system benign neoplasm and glioma susceptibility 1. An important gene associated with Central Nervous System Cancer is SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1), and among its related pathways/superpathways are Glioma and Gastric cancer. The drugs Carboplatin and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and breast, and related phenotypes are Decreased p24 protein expression and Decreased sensitivity to paclitaxel

Sources

Related Diseases for Central Nervous System Cancer

About this section

Diseases in the Nervous System Cancer family:

Central Nervous System Cancer

Diseases related to Central Nervous System Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 226)
# Related Disease Score Top Affiliating Genes
1 central nervous system benign neoplasm 32.9 GFAP SYP TP53
2 glioma susceptibility 1 32.6 GFAP IDH1 IDH2 TP53
3 ependymoma 32.6 EGFR GFAP MGMT NES NF2 SYP
4 central nervous system germ cell tumor 32.6 GFAP NES
5 spinal cancer 32.4 GFAP NF2 TP53
6 neurilemmomatosis 32.4 NF1 NF2 SMARCB1
7 central nervous system primitive neuroectodermal neoplasm 32.3 GFAP NES SYP TP53
8 glioma 32.2 CCND2-AS1 EGFR GLI1 IDH1 IDH2 NF1
9 oligodendroglioma 31.9 EGFR GFAP IDH1 IDH2 MGMT PTEN
10 subependymoma 30.8 GFAP NES SYP
11 brain cancer 30.8 AKT1 EGFR GFAP GLI1 IDH1 IDH2
12 subependymal giant cell astrocytoma 30.8 GFAP NES SYP
13 rhabdoid cancer 30.7 SMARCB1 SYP TP53
14 benign ependymoma 30.7 GFAP NF2 SYP
15 atypical teratoid rhabdoid tumor 30.7 GFAP SMARCB1 SYP TP53
16 tuberous sclerosis 30.5 AKT1 GFAP NF1 SYP
17 astroblastoma 30.5 GFAP NES SYP
18 anaplastic ependymoma 30.4 GFAP NF2 PTEN SYP
19 pleomorphic xanthoastrocytoma 30.3 GFAP IDH1 MGMT SMARCB1 SYP TP53
20 nervous system cancer 29.9 AKT1 EGFR GFAP IDH1 IDH2 MGMT
21 meningioma, familial 29.9 AKT1 GFAP NF1 NF2 PTEN SMARCB1
22 medulloblastoma 29.2 AKT1 EGFR GFAP GLI1 IDH1 MGMT
23 central nervous system hematologic cancer 11.4
24 mismatch repair cancer syndrome 11.3
25 glioma susceptibility 2 11.2
26 glioma susceptibility 3 11.2
27 glioma susceptibility 9 11.2
28 schwannomatosis 1 11.1
29 central nervous system sarcoma 11.1
30 cranial nerve neoplasm 11.1
31 central nervous system melanocytic neoplasm 11.1
32 central nervous system mesenchymal non-meningothelial tumor 11.1
33 meninges sarcoma 10.6 GFAP TP53
34 intraventricular meningioma 10.6 GFAP NF2
35 recurrent respiratory papillomatosis 10.6 EGFR TP53
36 malignant peritoneal mesothelioma 10.6 EGFR NF2
37 cytogenetically normal acute myeloid leukemia 10.6 IDH1 IDH2
38 septopreoptic holoprosencephaly 10.6 PTCH1 SHH
39 midline interhemispheric variant of holoprosencephaly 10.6 PTCH1 SHH
40 epithelioid malignant peripheral nerve sheath tumor 10.6 NF1 SMARCB1
41 rhabdoid meningioma 10.5 GFAP NF2 SMARCB1
42 oral cavity cancer 10.5 EGFR PTEN TP53
43 mixed glioma 10.5 GFAP IDH1 TP53
44 frontal convexity meningioma 10.5 GFAP TP53
45 cerebral convexity meningioma 10.5 GFAP NF2 TP53
46 respiratory system disease 10.5 AKT1 EGFR TP53
47 interval angle-closure glaucoma 10.5 IDH1 IDH2
48 intracranial chondrosarcoma 10.5 IDH1 IDH2 TP53
49 oligoastrocytoma 10.5 GFAP IDH2 MGMT
50 chordoid glioma 10.5 GFAP NF2 TP53

Graphical network of the top 20 diseases related to Central Nervous System Cancer:



Diseases related to Central Nervous System Cancer
Sources

Symptoms & Phenotypes for Central Nervous System Cancer

About this section

GenomeRNAi Phenotypes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased p24 protein expression GR00163-A-1 9.46 AKT1 EGFR IDH1 NF2
2 Decreased sensitivity to paclitaxel GR00112-A-0 8.96 NF1 PTEN
3 Increased proliferation GR00094-A 8.8 NF2 SMARCB1 TP53

MGI Mouse Phenotypes related to Central Nervous System Cancer:

47 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.44 AKT1 ARSA GFAP GLI1 NF1 NF2
2 homeostasis/metabolism MP:0005376 10.41 AKT1 ARSA EGFR GFAP IDH1 MGMT
3 cellular MP:0005384 10.4 AKT1 EGFR GFAP GLI1 NF1 PROM1
4 growth/size/body region MP:0005378 10.4 AKT1 EGFR GFAP GLI1 IDH1 NF1
5 mortality/aging MP:0010768 10.39 AKT1 EGFR GFAP GLI1 IDH1 MGMT
6 cardiovascular system MP:0005385 10.36 AKT1 EGFR GFAP IDH2 NF1 PROM1
7 immune system MP:0005387 10.34 AKT1 ARSA EGFR GFAP IDH1 NF1
8 embryo MP:0005380 10.3 AKT1 EGFR GLI1 NF1 NF2 PTCH1
9 nervous system MP:0003631 10.3 AKT1 ARSA EGFR GFAP GLI1 NF1
10 endocrine/exocrine gland MP:0005379 10.29 AKT1 EGFR GLI1 MGMT NF1 NF2
11 neoplasm MP:0002006 10.29 AKT1 EGFR GLI1 IDH2 MGMT NF1
12 digestive/alimentary MP:0005381 10.26 EGFR GFAP GLI1 NF1 PTCH1 PTEN
13 craniofacial MP:0005382 10.16 EGFR GLI1 NF1 NF2 PTCH1 SHH
14 integument MP:0010771 10.15 AKT1 EGFR NF1 NF2 PTCH1 PTEN
15 muscle MP:0005369 10.15 AKT1 EGFR GFAP NF1 PTCH1 PTEN
16 normal MP:0002873 10.14 AKT1 EGFR GFAP GLI1 NF1 PROM1
17 liver/biliary system MP:0005370 10.13 AKT1 EGFR NF1 NF2 PTEN SHH
18 hearing/vestibular/ear MP:0005377 10.12 ARSA EGFR NF1 NF2 PTCH1 SHH
19 limbs/digits/tail MP:0005371 10.08 EGFR GLI1 NF1 PTCH1 PTEN SHH
20 no phenotypic analysis MP:0003012 9.98 EGFR GLI1 MGMT PROM1 PTCH1 SHH
21 renal/urinary system MP:0005367 9.92 EGFR GLI1 NF1 NF2 PTCH1 PTEN
22 reproductive system MP:0005389 9.91 AKT1 EGFR GLI1 NF2 PTCH1 PTEN
23 respiratory system MP:0005388 9.9 AKT1 EGFR GLI1 IDH1 MGMT NF1
24 pigmentation MP:0001186 9.85 EGFR NF1 PROM1 PTCH1 PTEN TP53
25 skeleton MP:0005390 9.61 AKT1 EGFR IDH1 NF1 NF2 PTCH1
26 vision/eye MP:0005391 9.32 EGFR GFAP NF1 NF2 PROM1 PTCH1
Sources

Drugs & Therapeutics for Central Nervous System Cancer

About this section

Drugs for Central Nervous System Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 110)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
2
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
3
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
4
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
6 Etoposide phosphate Phase 2, Phase 3,Phase 1
7
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
8
Carmustine Approved, Investigational Phase 2 154-93-8 2578
9
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
10
Temozolomide Approved, Investigational Phase 2,Phase 1,Early Phase 1 85622-93-1 5394
11
Phenylacetic acid Approved Phase 2 103-82-2 999
12
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
13
Methadone Approved, Illicit Phase 1, Phase 2 76-99-3 4095
14
Guaifenesin Approved, Investigational, Vet_approved Phase 1, Phase 2 93-14-1 3516
15
Bevacizumab Approved, Investigational Phase 2,Phase 1,Early Phase 1 216974-75-3
16
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
17
nivolumab Approved Phase 2,Phase 1 946414-94-4
18
Pembrolizumab Approved Phase 2 1374853-91-4
19
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
20
Iodine Approved, Investigational Phase 2,Not Applicable 7553-56-2 807
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
23
Promethazine Approved, Investigational Phase 2 60-87-7 4927
24
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
25
Acetaminophen Approved Phase 2 103-90-2 1983
26
Ipilimumab Approved Phase 2 477202-00-9
27 Immunologic Factors Phase 2,Phase 1,Not Applicable
28 Immunosuppressive Agents Phase 2,Phase 1
29 Antirheumatic Agents Phase 2
30 Topoisomerase Inhibitors Phase 2,Phase 1,Early Phase 1
31 Antineoplastic Agents, Alkylating Phase 2,Phase 1,Early Phase 1
32 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
33 Alkylating Agents Phase 2,Phase 1,Early Phase 1
34 4-phenylbutyric acid Phase 2
35 Liver Extracts Phase 2,Phase 1
36 Cytochrome P-450 CYP3A Inhibitors Phase 2
37 Angiogenesis Modulating Agents Phase 2,Phase 1,Early Phase 1
38 Cytochrome P-450 Enzyme Inhibitors Phase 2
39 Angiogenesis Inhibitors Phase 2,Phase 1,Early Phase 1
40 Cytochrome P-450 CYP3A Inducers Phase 2
41 Protein Kinase Inhibitors Phase 2,Phase 1
42 Narcotics Phase 1, Phase 2
43 Central Nervous System Depressants Phase 1, Phase 2
44 Chlorpheniramine, phenylpropanolamine drug combination Phase 1, Phase 2
45 D-methadone Phase 1, Phase 2
46 Peripheral Nervous System Agents Phase 1, Phase 2
47 Analgesics, Opioid Phase 1, Phase 2
48 Antitussive Agents Phase 1, Phase 2
49 Respiratory System Agents Phase 1, Phase 2
50 Analgesics, Non-Narcotic Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
2 Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer Completed NCT00007982 Phase 2 carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
3 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
4 Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors Completed NCT00006450 Phase 2 Phenylbutyrate
5 Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors Completed NCT02038218 Phase 2 4-Demethyl-4-cholestryloxycarbonylpenclomedine
6 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
7 Study of D-Methadone in Patients With Chronic Pain Completed NCT00588640 Phase 1, Phase 2 d-Methadone;D-methadone;placebo
8 Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
9 Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) Recruiting NCT03405792 Phase 2 Temozolomide (TMZ);Pembrolizumab
10 TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma Recruiting NCT02663271 Phase 2 Bevacizumab
11 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2 SIACI of Erbitux and Bevacizumab
12 Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03698994 Phase 2 Ulixertinib
13 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
14 Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers Recruiting NCT02992964 Phase 1, Phase 2 Nivolumab
15 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
16 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
17 An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies Active, not recruiting NCT03130959 Phase 2
18 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma Active, not recruiting NCT00588523 Phase 2 temozolomide followed by high dose busulfan and thiotepa
19 Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Unknown status NCT00004129 Phase 1
20 Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer Completed NCT00053118 Phase 1 carboplatin;etoposide
21 Busulfan in Treating Children and Adolescents With Refractory CNS Cancer Completed NCT00006246 Phase 1 busulfan
22 A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors Completed NCT00756340 Phase 1 Bevacizumab;Everolimus
23 A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer Completed NCT00001683 Phase 1 COL-3
24 Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors Completed NCT00594633 Phase 1
25 SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00015899 Phase 1 lonafarnib
26 EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients Completed NCT00328458 Phase 1 EPO906 (epothilone B)
27 Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors Completed NCT01639911 Phase 1 Alisertib;Pazopanib
28 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
29 Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors Completed NCT00019630 Phase 1 doxorubicin HCl liposome
30 Stereotactic Radiosurgery in Treating Patients With Brain Tumors Completed NCT00019578 Phase 1
31 Phase I Study of APX005M in Pediatric CNS Tumors Recruiting NCT03389802 Phase 1
32 SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Recruiting NCT03434262 Phase 1 Gemcitabine;ribociclib;sonidegib;trametinib
33 Multi-antigen T Cell Infusion Against Neuro-oncologic Disease Recruiting NCT03652545 Phase 1
34 Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors Recruiting NCT03565367 Phase 1 Hyperpolarized Carbon C 13 Pyruvate
35 A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Recruiting NCT02564198 Phase 1 Ramucirumab
36 ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas Not yet recruiting NCT03922555 Phase 1 ASTX727
37 MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer Terminated NCT00572182 Phase 1 MK-0752
38 Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy Terminated NCT00629187 Phase 1 Temozolomide
39 Melphalan With BBBD in Treating Patients With Brain Malignancies Terminated NCT00253721 Phase 1 Melphalan
40 SU5416 in Treating Children With Recurrent or Progressive Brain Tumors Terminated NCT00006247 Phase 1 semaxanib
41 Language Function in Patients With Brain Tumors Completed NCT00599703
42 Quality of Life in Children With Cancer Completed NCT03190499
43 Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults Completed NCT03630861
44 Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Completed NCT00013533 Early Phase 1
45 Cognitive Function After Treatment of Primary CNS Malignancy Recruiting NCT03055364
46 Natural History of and Specimen Banking for People With Tumors of the Central Nervous System Recruiting NCT02851706
47 Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System Recruiting NCT02392078
48 Integrated Cancer Repository for Cancer Research Recruiting NCT02012699
49 Immunological Profile of Solid Tumors Sample Recruiting NCT03311100
50 Imaging Brain Tumors With FACBC and Methionine Active, not recruiting NCT00597246 Not Applicable FACBC, Methionine

Search NIH Clinical Center for Central Nervous System Cancer

Cochrane evidence based reviews: central nervous system neoplasms

Sources

Genetic Tests for Central Nervous System Cancer

About this section
Sources

Anatomical Context for Central Nervous System Cancer

About this section

MalaCards organs/tissues related to Central Nervous System Cancer:

42
Brain, Lung, Breast, Liver, Testes, T Cells, Cerebellum

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Cancer:

20
The Central Nervous System
Sources

Publications for Central Nervous System Cancer

About this section

Articles related to Central Nervous System Cancer:

(show all 20)
# Title Authors Year
1
Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States. ( 30350913 )
2019
2
Neuropsychological disorders in non-central nervous system cancer: a review of objective cognitive impairment, depression, and related rehabilitation options. ( 31049790 )
2019
3
Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. ( 29374660 )
2018
4
The Complex Diagnostic Challenge in Children With Non-Central Nervous System Cancer and Cerebellar Mutism. ( 28497710 )
2017
5
Brain cortical structural differences between non-central nervous system cancer patients treated with and without chemotherapy compared to non-cancer controls: a cross-sectional pilot MRI study using clinically-indicated scans. ( 30034079 )
2017
6
Meta-Analysis of the Effects of Neuropsychological Interventions on Cognitive Function in Non-Central Nervous System Cancer Survivors. ( 27151596 )
2016
7
Brain and central nervous system cancer incidence in navarre (Spain), 1973-2008 and projections for 2014. ( 25561983 )
2015
8
Vocational identity, positive affect, and career thoughts in a group of young adult central nervous system cancer survivors. ( 25035908 )
2014
9
Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients. ( 23661397 )
2013
10
Medulloblastoma and Brucellosis - Molecular Evidence of Brucella sp in Association with Central Nervous System Cancer. ( 21475718 )
2011
11
Comparison of time trends in brain and central nervous system cancer mortality (1990-2006) between countries based on the WHO mortality database. ( 21273379 )
2011
12
Pain in children with central nervous system cancer: a review of the literature. ( 20591796 )
2010
13
Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. ( 20816315 )
2010
14
School-aged children after the end of successful treatment of non-central nervous system cancer: longitudinal assessment of health-related quality of life, anxiety and coping. ( 19594611 )
2009
15
Neuropsychological sequelae of non-central nervous system cancer and cancer therapy. ( 18415683 )
2008
16
Comparison of time trends in brain central nervous system cancer incidence (1973-97) in East Asia, Europe and USA, from Cancer Incidence in Five Continents Vols IV-VIII. ( 18772173 )
2008
17
Cytotoxicity and oncostatic activity of the thiazolidinedione derivative CGP 52608 on central nervous system cancer cells. ( 15194216 )
2004
18
Exploitation of immune mechanisms in the treatment of central nervous system cancer. ( 10914414 )
2000
19
Human malignant astrocytoma xenografts migrate in rat brain: a model for central nervous system cancer research. ( 2651679 )
1989
20
Brain and central nervous system cancer mortality in U. S. rubber workers. ( 6953785 )
1982
Sources

Variations for Central Nervous System Cancer

About this section

ClinVar genetic disease variations for Central Nervous System Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 SMARCB1 NM_003073.4(SMARCB1): c.351dup (p.Thr118Hisfs) duplication Pathogenic rs1555876140 GRCh38 Chromosome 22, 23793677: 23793677
2 SMARCB1 NM_003073.4(SMARCB1): c.351dup (p.Thr118Hisfs) duplication Pathogenic rs1555876140 GRCh37 Chromosome 22, 24135864: 24135864
Sources

Expression for Central Nervous System Cancer

About this section
Search GEO for disease gene expression data for Central Nervous System Cancer.
Sources

Pathways for Central Nervous System Cancer

About this section

Pathways related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Glioma 38
Show member pathways
 12.58 AKT1 EGFR NF1 PTEN TP53
2
Gastric cancer 38
Show member pathways
 12.55 AKT1 EGFR PTEN SHH SMARCB1 TP53
3
Pathways in cancer 38
12.53 AKT1 EGFR GLI1 PTCH1 PTEN SHH
4
Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling 66
Show member pathways
 12.3 GLI1 PTCH1 SHH TP53
5
Wnt / Hedgehog / Notch 4
12.11 GLI1 PROM1 PTCH1 SHH
6
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.08 AKT1 EGFR PTEN TP53
7
Proteoglycans in cancer 38
12.07 AKT1 EGFR PTCH1 SHH TP53
8
AKT Signaling Pathway 68
12.01 AKT1 EGFR PTEN TP53
9
Integrated Breast Cancer Pathway 1
11.91 AKT1 EGFR NF1 PTEN TP53
10
Hedgehog Pathway 73
Show member pathways
 11.89 AKT1 GLI1 PTCH1 SHH
11
Small cell lung cancer 38
11.76 AKT1 PTEN TP53
12
Androgen receptor signaling pathway 1
11.74 AKT1 EGFR PTEN
13
TP53 Regulates Metabolic Genes 67
11.7 AKT1 PTEN TP53
14
Pathways Affected in Adenoid Cystic Carcinoma 1
11.57 AKT1 PTEN TP53
15
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.45 GFAP NES PROM1 SHH SYP
16
Copper homeostasis 1
11.44 AKT1 PTEN TP53
17
Integrated Cancer Pathway 1
11.36 AKT1 PTEN TP53
18
Development_Hedgehog and PTH signaling pathways in bone and cartilage development 23
11.26 GLI1 PTCH1 SHH
19
Glioblastoma Multiforme 65
11.21 AKT1 EGFR MGMT NF1 NF2 PTEN
20
Central carbon metabolism in cancer 38
11.17 AKT1 EGFR IDH1 PTEN TP53
21
Signaling events mediated by the Hedgehog family 1
Show member pathways
 11.15 AKT1 PTCH1 SHH
22
Extracellular vesicle-mediated signaling in recipient cells 1
11.09 AKT1 EGFR PROM1
23
Cytosine methylation 1
Show member pathways
 10.73 IDH1 IDH2
24
Glypican 3 network 1
10.47 PTCH1 SHH
Sources

GO Terms for Central Nervous System Cancer

About this section

Biological processes related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.99 AKT1 EGFR PTEN SHH TP53
2 brain development GO:0007420 9.95 NES NF1 NF2 PTCH1
3 negative regulation of cell proliferation GO:0008285 9.85 NF1 NF2 PTCH1 PTEN SMARCB1 TP53
4 negative regulation of cell migration GO:0030336 9.83 NF1 NF2 PTEN SHH
5 negative regulation of protein kinase activity GO:0006469 9.82 AKT1 NF1 NF2
6 canonical Wnt signaling pathway GO:0060070 9.81 GLI1 PTEN SHH
7 smoothened signaling pathway GO:0007224 9.79 GLI1 PTCH1 SHH
8 central nervous system development GO:0007417 9.73 ARSA NES PTEN SHH
9 dorsal/ventral pattern formation GO:0009953 9.72 GLI1 PTCH1 SHH
10 liver regeneration GO:0097421 9.69 EGFR GLI1 PTCH1
11 dorsal/ventral neural tube patterning GO:0021904 9.66 PTCH1 SHH
12 ectoderm development GO:0007398 9.65 NF2 SHH
13 regulation of synaptic transmission, GABAergic GO:0032228 9.65 NF1 PTEN
14 negative regulation of cell size GO:0045792 9.64 AKT1 PTEN
15 forebrain morphogenesis GO:0048853 9.63 NF1 PTEN
16 tricarboxylic acid cycle GO:0006099 9.63 IDH1 IDH2 SUCLG2
17 NADP metabolic process GO:0006739 9.62 IDH1 IDH2
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 EGFR TP53
19 Bergmann glial cell differentiation GO:0060020 9.61 GFAP SHH
20 regulation of protein localization to nucleus GO:1900180 9.6 NF2 SHH
21 isocitrate metabolic process GO:0006102 9.58 IDH1 IDH2
22 cellular response to decreased oxygen levels GO:0036294 9.57 AKT1 PTEN
23 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.56 GLI1 SHH
24 regulation of cell proliferation GO:0042127 9.55 EGFR NF1 NF2 PTCH1 SHH
25 digestive tract morphogenesis GO:0048546 9.5 EGFR GLI1 SHH
26 response to UV-A GO:0070141 9.49 AKT1 EGFR
27 ventral midline development GO:0007418 9.48 GLI1 SHH
28 prostate gland development GO:0030850 9.43 GLI1 PTCH1 SHH
29 glyoxylate cycle GO:0006097 9.4 IDH1 IDH2
30 mammary gland epithelial cell differentiation GO:0060644 9.13 AKT1 MGMT PTCH1
31 response to organic cyclic compound GO:0014070 9.02 EGFR IDH1 MGMT PTCH1 PTEN
32 positive regulation of transcription, DNA-templated GO:0045893 10.05 AKT1 EGFR GLI1 PTCH1 SHH TP53
33 negative regulation of apoptotic process GO:0043066 10.01 AKT1 EGFR MGMT PTEN SHH TP53

Molecular functions related to Central Nervous System Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 AKT1 EGFR GFAP IDH1 PTEN SYP
2 nitric-oxide synthase regulator activity GO:0030235 9.37 AKT1 EGFR
3 cholesterol binding GO:0015485 9.33 PROM1 PTCH1 SYP
4 patched binding GO:0005113 9.32 PTCH1 SHH
5 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
6 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2
Sources

Sources for Central Nervous System Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....